APTOSE BIOSCIENCES INC (APTO)
CA03835T3091 - Common Stock
Friday's session: most active stocks
Let's have a look at the most active stocks in today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Which stocks are moving before the opening bell on Friday?
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Stay updated with the stocks that are on the move in today's after-hours session.
Stay updated with the stocks that are on the move in today's after-hours session.
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Positive Decision by Nasdaq Hearings Panel ...
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML...
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML...
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations ...
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering ...
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering ...
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy ...
Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML
Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML...
Aptose Announces Results from Special Meeting of Shareholders
Aptose Announces Results from Special Meeting of Shareholders
Aptose Announces Results from Special Meeting of Shareholders ...
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib...
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Announces Adjournment of its Special Meeting of Shareholders...
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the second quarter o...
Aptose Reports Results for the Second Quarter 2024
Aptose Reports Results for the Second Quarter 2024
Aptose Reports Results for the Second Quarter 2024...
Aptose Announces Receipt of Deficiency Notice from Nasdaq
Aptose Announces Receipt of Deficiency Notice from Nasdaq
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Results from Annual and Special Meeting of Shareholders...
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress...